SCHEMBL8288223

SCHEMBL8288223

N[C@@H](CC(=O)N1CCC[C@H]1CN1CCCC1)Cc1cccc(Cl)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 9/20 0.70
DPP8 Q6V1X1 6/20 0.70
DPP9 Q86TI2 5/20 0.70
DPP7 Q9UHL4 5/20 0.70
HRH3 Q9Y5N1 3/20 0.51
OPRK1 P41145 4/20 0.50
NPC1 O15118 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
NFKB1 P19838 1/20 0.50
CYP2C19 P33261 1/20 0.50
OPRD1 P41143 1/20 0.50
HIF1A Q16665 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
BLM P54132 1/20 0.49
PMP22 Q01453 1/20 0.49
DRD4 P21917 1/20 0.49
SLC6A3 Q01959 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14307824 0.82 DPP4 (0.74) DPP4DPP8DPP9DPP7CYP2D6
SCHEMBL8290051 0.82 DPP4 (1.00) DPP4DPP8DPP9DPP7CYP2D6
SCHEMBL8289103 0.81 DPP4 (1.00) DPP4DPP8DPP9DPP7
SCHEMBL8289057 0.81 DPP4 (1.00) DPP4DPP8DPP9DPP7CYP2D6
SCHEMBL4664774 0.80 DPP4 (0.62) DPP4DPP8DPP9DPP7CYP2D6
SCHEMBL8289125 0.80 DPP4 (0.70) DPP4DPP8DPP9DPP7CYP2D6
SCHEMBL8289127 0.80 DPP4 (1.00) DPP4DPP8DPP9DPP7CYP2D6
SCHEMBL14421764 0.80 DPP4 (1.00) DPP4DPP8DPP9DPP7CYP2D6
SCHEMBL8474063 0.78 DPP4 (0.76) DPP4DPP8DPP9DPP7
SCHEMBL23752465 0.77 DPP4 (1.00) DPP4DPP8DPP9DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080027035-A1 Dpp-Iv Inhibitors GRAFFINITY PHARMACEUTICALS AG (DE) 2008-01-31 US disclosed
US-20080027035-A1 Dpp-Iv Inhibitors GRAFFINITY PHARMACEUTICALS AG (DE) 2008-01-31 US disclosed
EP-1613304-B1 DPP-IV INHIBITORS SANTHERA PHARMACEUTICALS CH (CH) 2007-09-12 EP disclosed
WO-2005056003-A1 DPP-IV INHIBITORS SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2005-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027035-A1 Dpp-Iv Inhibitors DPP4, DPP7, DPP3 DPP4 1/4885DPP8 5/4885DPP9 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.